Sanofi/Genzyme Pompe drug Lumizyme gains expanded use
This article was originally published in Scrip
Executive Summary
The FDA on 1 August gave its OK to permit Sanofi subsidiary Genzyme to market Lumizyme (alglucosidase alfa) as a treatment for all patients of any age or phenotype with Pompe disease – expanding the drug's use.